lianhua qingwen contraindication

Although the data were far from adequate, the latest advances had shown the benefits of LHQW in COVID-19, especially in combination with other antiviral drugs. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools. Please be informed that only the Lianhua . All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Jiao Qu revised the manuscript. Combined with western medicine conventional therapy in the treatment of 63 suspected cases of Coronavirus Disease 2019. It is urgent to develop effective drugs to contain and treat COVID-19. Although the results obtained for influenza were consistent with our findings, the control group in this earlier study was treated with a single drug while our control groups were treated with antiviral drugs, conventional antibiotics or symptomatic therapy. Besides, the collected clinical trials involving TCM in the treatment of COVID-19 were mainly from China and published in Chinese, and thus further well-designed multicenter RCTs from different countries will be more attractive before a definitive conclusion can be drawn. The current. In recent years, LHQW has played a significant role in the prevention and control of viral public health events (Yao et al., 2020), and is widely accepted as a representative antiviral Chinese medicine in China. doi:10.1056/NEJMc2008043, Cao, L. J. Available at: http://www.plantsoftheworldonline.org (Accessed December 18, 2021). However, both groups did not differ in the rate of conversion to severe cases or viral assay findings. Efficacy of Huoxiang Zhengqi Dropping Pills and Lianhua Qingwen Granules in Treatment of Covid-19: a Randomized Controlled Trial. Vahl. 28 (1), 1332. In the evaluation of treating disease, significant reduced incidence of adverse reactions during treatment of influenza A (H1N1) and influenza were detected in the LHQW group. Lian-Di Kan, Ye-Cheng Jin and Hong-Mei Fang were responsible for the conception and design of the review. Liu, X. Y. Heterogeneity was evaluated using I2 statistic. Tian S., Song X., Wang Y., Wang X., Mou Y., Chen Q., Zhao H., Ma K., Wu Z., Yu H., Han X., Wang H., Wang S., Ji X., Zhang Y. Chinese herbal medicine Baoyuan Jiedu decoction inhibits the accumulation of myeloid derived suppressor cells in pre-metastatic niche of lung via TGF-/CCL9 pathway. Wang et al. doi:10.26434/chemrxiv.12016236.v1. The incidence of nervous system damage was lower in the LHQW group compared to the conventional drug group (RR = 0.24, 95% CI = 0.180.32, p < 0.001). Effects of Four Types of Integrated Chinese and Western Medicines for the Treatment of Covid-19 in china: a Network Meta-Analysis. The trim and fill method was employed in cases where publication bias existed (Duval and Tweedie, 2000). Finally, all adverse reactions were described solely based on grouping of patients into treatment and control categories and no data were obtained according to gender stratification, which limited further analysis. Clinical Practice Guideline on Treating Influenza in Adult Patients with Chinese Patent Medicines. Secondly, separate evaluations were further performed for different diseases and types of adverse reactions. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., Niu P., Zhan F., Ma X., Wang D. A novel coronavirus from patients with pneumonia in China, 2019. Immune imbalance mechanism and intervention strategy in patients with coronavirus disease 2019 (COVID-19). In response to the severe SARS-CoV-2 attack, TCM has gained high usage in recent several months especially in China [47]. J. Pharmacovigilance. Subgroup analysis additionally demonstrated LHQW group has a reduced incidence of rash, nausea or vomiting, and resurgence of disease. Now, there are no study results posted on ClinicalTrials.gov for this study yet. Anal. [Caprifoliaceae; Lonicerae Japonicae Flos] (255g), Ephedra sinica Stapf [Ephedraceae; Ephedrae Botanical drug] (85g), Prunus armeniaca L. [Rosaceae; Armeniacae Semen Amarum] (85g), Gypsum Fibrosum (255g), Isatis indigotica Fort. Though no specific drug has been developed so far, emerging agents have been confirmed effective or potentially beneficial to restrain it. Kunming: Kunming University of technology. There was a reduced risk of skin and its appendage damage in the LHQW group compared to the conventional drug group (RR = 0.63, 95% CI = 0.440.92, p = 0.015). The majority of studies lacked sufficient description of allocation concealment and therefore, the project was predominantly evaluated as unclear risk of bias. Although the blinding method was not reported, since some symptom indicators needed measurement with instruments, assessment of symptom indicators was unlikely to be affected by the lack of blinding. Meta-analysis and systematic review of efficacy and safety of Lianhua Qingwen in adjuvant treatment of adult pneumonia. Results were reported as risk ratio (RR) with 95% confidence interval (CI). Drug Related Hospital Admissions: the Role of Definitions and Intensity of Data Collection, and the Possibility of Prevention. Available at: http://www.yiling.cn/contents/75/132.html (Accessed September 14, 2021). 12 (12), 753759754755. Based Complement. Identification of a pharmacological biomarker for the bioassay-based quality control of a thirteen-component TCM formula (Lianhua Qingwen) used in treating influenza A virus (H1N1) infection. Li Q., Yin J., Ran Q.S., Yang Q., Liu L., Zhao Z., Li Y.J., Chen Y., Sun L.D., Wang Y.J., Weng X.G., Cai W.Y., Zhu X.X. doi:10.1126/science.367.6485.1412, Lei, X. doi:10.1111/j.1365-2796.1990.tb00199.x, Higgins, J. P., Altman, D. G., Gtzsche, P. C., Jni, P., Moher, D., Oxman, A. D., et al. Clin. Some notable dangerous reactions include heart attacks, strokes, seizures, and sudden deaths. Vahl (Lianqiao); Lonicera japonica Thunb. In the evaluation of security indexes, our meta-analysis revealed that LHQW group having a lower level of adverse reactions compared to the conventional drug group, such as respiratory system damage, skin and its appendage damage, nervous system damage, gastrointestinal system damage and other adverse reactions. recently published a clinical study on the treatment of mild COVID-19 with LHQW granules (6g, tid) combined with abidor (0.2g, tid) [44]. [8] A January 2022 meta-analysis from China reports that it may cause GI discomfort, rashes and itches, dry mouth, and dizziness, but emphasizes that the effects are more common with "conventional treatment". No meta-regression was performed for COVID-19 pneumonia due to the limited number of studies. [12], In April 2022, the Financial Times reported that the leading COVID-19 health official in the PRC, the famous epidemiologist and pulmonologist Zhong Nanshan - who has also been the most prominent scientific promoter of Lianhua Qingwen - had undisclosed prior investments in large stakeholdings in corporations producing Lianhua Qingwen and other treatments under question. The clinical application experience of LHQW has improved over the years, the clinical considers the patients condition, physical quality, and age, controls the amount of LHQW prescribed accordingly and thereby, reduced the likelihood of adverse reactions. Trials. A Trial of Lopinavir-Ritonavir in Covid-19. ex DC. 343, d5928. Pulmonary Rale.Eighteen studies reported an effect on the duration of pulmonary rale. The search keywords for screening the literature information were virus, COVID-19, or SARS-CoV-2, and Lianhua Qingwen. Some composition of LHQW can cause damage to the stomach and intestines, supporting the possibility of injurious effects on the gastrointestinal system: for thia suspensa (Thunb.) Lianhua Qingwen (simplified Chinese: ; traditional Chinese: ; lit. Keywords: Lianhua Qingwen, adverse reaction, COVID-19, influenza, traditional Chinese medicine, meta-analysis, Citation: Hu C, He B, Gong F, Liang M, Zhao D and Zhang G (2022) The Adverse Reactions of Lianhua Qingwen Capsule/Granule Compared With Conventional Drug in Clinical Application: A Meta-Analysis. Data from our meta-analysis also failed to compare the security of LHQW with conventional drugs for treatment of COVID-19 pneumonia, which requires further investigation. Six studies reported the adverse reactions of abnormal white blood cells and reticuloendothelial system. (2002). Twenty-three studies on other diseases were included, with 12 reporting adverse reactions. This review has introduced the advances of LHQW in anti-viral treatment, intending to provide ideas for the timely treatment of COVID-19 patients. J. Chin. Fujian J. 13 (08), 676681. There was no statistically significant difference in the incidence of adverse reactions during treatment of viral influenza between the LHQW group and the conventional drug group (RR = 0.75, 95% CI = 0.471.21, p = 0.244). Related tags TCM COVID-19 China A two-week clinical trial led by renowned Chinese pulmonologist Zhong Nanshan has shown that consuming the botanical TCM product Lianhua Qingwen (LH) capsules and undergoing the standard . Adverse Drug Reactions to Antibiotics Observed in Two Pulmonology Divisions of Catanzaro, Italy: a Six-Year Retrospective Study. [5], Sources of its formulation reportedly consist of:[6], The medicine is both in capsule and granular form. Traditional Chinese medicine has accumulated substantial clinical experience over thousands of years. This review provides comprehensive evidence of LHQW as a complementary strategy for treating COVID-19. The LHQW group has a reduced incidence of gastrointestinal system damage than the conventional drug group (RR = 0.83, 95% CI = 0.740.93, p = 0.002). Measuring Inconsistency in Meta-Analyses. Subgroup, sensitivity and meta-regression analyses were conducted to determine the potential sources of heterogeneity. Traditional Chinese medicine for pulmonary fibrosis therapy: progress and future prospects. Yang C.X., Qu J., Liu Y.T., Meng S.W., Wang B.L., Feng M.Q., Sun Y. [7] In the United States, the FDA is advising consumers not to purchase or use Lianhua Qingwen, stating that it has not been approved or authorized by FDA and is being misleadingly represented as safe and/or effective for the treatment or prevention of COVID-19. Wang L., Yang Z.H., Zhang H.R., Yu H.X., Yang K., Fu B.H., Yang H.T. Other related clinical studies also revealed that LHQW significantly improved the symptoms in COVID-19 patients and reduced the duration of fever, fatigue and cough and so forth, which provide preliminary research evidence for clinical treatment of COVID-19 [45,46]. A total of 2,511 citations were identified, among which 1,796 irrelevant, animal studies or duplicate studies were excluded, for screen of titles and abstracts. (2015). Modern pharmacological studies have shown that Lianhua Qingwen Prescription, as a traditional Chinese medicine prescription, has extensive antiviral and immunomodulatory effects on a series of influenza viruses. (2021). Copyright 2022 Hu, He, Gong, Liang, Zhao and Zhang. In addition, LHQW capsules could inhibit both Victoria and Yamagata lineages of influenza B virus (IBV) with the 50 % inhibitive concentrations ranging from 0.2280.150 to 0.7540.161mg/mL [26]. 17 (13), 6264. The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.764774/full#supplementary-material, Ahsan, W., Javed, S., Bratty, M. A., Alhazmi, H. A., and Najmi, A. High-quality randomized controlled trials conducted over the long-term from multiple countries are warranted to further validate the efficacy and safety of LHQW. Use Overdosage Contraindications Special Precautions Adverse Reactions Storage MIMS Class ATC . Considerable research to date has focused on the clinical efficacy of LHQW, the safety of LHQW is additionally an important consideration for clinical application that should not be neglected. A multi-center, randomized, double-blind, and placebo-controlled phase II clinical study, sponsored by Yiling Pharmaceutical Inc., was conducted to investigate the safety and efficacy of two doses of LHQW capsule compared to placebo in subjects with acute uncomplicated influenza in the U.S.A (https://www.clinicaltrials.gov/ct2/show/study/{"type":"clinical-trial","attrs":{"text":"NCT02867358","term_id":"NCT02867358"}}NCT02867358). Therefore, we conducted a systematic review of the . [13], A 2020 "randomized controlled trial" of LHQW involving Zhong was also found in April 2022 to have undisclosed funding from Yiling Pharmaceuticals, forcing an erratum. showed that the usual treatment in combination with LHQW capsules (4 capsules thrice daily for 14 days) had significantly higher recovery rate, and shorter median time to symptom recovery, as compared with control group [43]. Materia Med. Front. Lianhua Qingwen, the traditional Chinese medicine recently approved for use in the Philippines by the country's Food and Drugs Administration (FDA), only treats symptoms of the coronavirus disease 2019 (COVID-19), and not the disease itself, a traditional Chinese medicine physician said Tuesday. Accordingly, other biases were defined as low risk of bias. The risk of bias data is presented as a percentage, as shown in Figure 2. LYY19H280006, No. Lu Z.J., Wu L.Y., Mou Y.Y., Duan H.M., Chen R.C., Xiao Y., Zheng W.J. Furthermore, they identified two important metabolites, prostaglandin F2 and arachidonic acid, and their arachidonic acid metabolism pathway, as vital indicators of LHQW in treating influenza by using serum metabolomics analysis [19]. A recent meta-analysis came from Zhang and Liu, (2014), focused on treatment for influenza A (H1N1) with LHQW in conjunction with oseltamivir. Qualitative and Quantitative Analysis of the Major Constituents in Chinese Medical Preparation Lianhua-Qingwen Capsule by UPLC-DAD-QTOF-MS. ScientificWorldJournal. Subgroup analysis showed a lower level of nausea or vomiting in LHQW group (RR = 0.60, 95% CI = 0.480.74, p < 0.001), no statistical difference was detected for other symptoms of gastrointestinal system damage. National Library of Medicine Homogeneity of baseline data was reported in most studies. Trim and Fill: a Simple Funnel-Plot-Based Method of Testing and Adjusting for Publication Bias in Meta-Analysis. Hu K., Guan W.J., Bi Y., Zhang W., Li L., Zhang B., Liu Q., Song Y., Li X., Duan Z., Zheng Q., Yang Z., Liang J., Han M., Ruan L., Wu C., Zhang Y., Jia Z.H., Zhong N.S. [Caprifoliaceae; Lonicerae Japonicae Flos], Gypsum Fibrosum, Isatis indigotica Fort. Lianhua Qingwen combined with conventional antiviral Western Medicine may be a useful treatment for prediabetes. sharing sensitive information, make sure youre on a federal A network analysis of the Chinese medicine Lianhua-Qingwen formula to identify its main effective components. Lianhua Qingwen (LHQW) is a classical Chinese medical preparation, while one of its prescription compositions Maxingshigan Decoction has a history of more than thousand years to treat plague, and exhibits antiviral and lung protection actions [15,16].

Wellcare Healthy Rewards Login, Articles L